



## SVANOVIR® CSFV-Ab

# The well-balanced assay for detection of Classical Swine Fever Virus

**SUMMARY** | SVANOVIR® CSFV-Ab assay is an indirect ELISA based on the recombinant E2 protein, detecting exposure to Classical Swine Fever Virus. In comprehensive studies including an OIE reference panel and serum samples from domestic pigs and wild boars, the SVANOVIR® CSFV-Ab assay shows a well-balanced specificity and sensitivity.



### **YOUR CHALLENGE** is a chameleonic contagious disease

Classical Swine Fever (CSF) is a highly contagious disease, easily transmitted by direct contact, aerosols and feeding with contaminated waste food. Strains of the CSF virus, which belongs to the genus *Pestivirus*, show a high variability in virulence resulting in acute to chronic infections. CSF decreases production through high mortality or unspecific symptoms such as low performance in fattening and breeding herds. Wild boars can be reservoirs and pose a risk for infection of domestic pigs.

### **YOUR GOAL** is the timely verification of presence or absence of exposure

In many countries Classical Swine Fever Virus (CSFV) is endemic, whereas some countries have achieved disease-free status. Timely, early detection is essential for preventing spread of the virus and strengthening biosecurity. Specific serological tests are needed to avoid false positive results owing to the cross-reactivity with other members of the genus *Pestivirus*.

### **Well balanced assay:**

Detects exposure of CSFV infections at the herd level

### **Fulfills test requirements** according to OIE guide-lines

- Detects exposure to high, medium and low virulent strains of CSFV
- Detects antibodies in sera of convalescent pigs (>21dpi) and during early phase of infection (< 21dpi) according to OIE panel

**Enables detection of antibodies** generated by vaccination

**Validated in domestic pigs and wild boars**

## ASSAY OVERVIEW



### SVANOVIR® CSFV-Ab

<b>Species</b>	Porcine (incl. wild boars)		
<b>Samples</b>	Serum/plasma		
<b>Type</b>	Indirect ELISA based on recombinant E2 protein		
<b>Article number</b>	<b>Samples*</b>	<b>Plates</b>	<b>Format</b>
10-7800-02	184	2	Strips
10-7800-10	920	10	Plates

\*Samples: Max number of samples for analysis, wells for kit controls excluded.

This well-balanced assay is a reliable tool, on a representative sample size, to demonstrate a population's freedom of infection, in trading situations and surveillance programmes. In areas controlling CSFV by vaccination, the assay enables the detection of antibodies generated by vaccination.

**Ideal technology** for screening and high sample throughput

**Effective handling and convenient in use** with ready-to-use conjugate and simple protocol


**Flexibility in daily routines** with short and overnight incubation

**High quality** - thoroughly validated and manufactured under strict ISO 9001:2008 standardised procedures in Sweden

**Multilingual labels**

## YOUR SUPPORT

From 9am-4pm CET call:

 +46 18 65 49 15

 [customer.service@svanova.com](mailto:customer.service@svanova.com)

## PERFORMANCE CHARACTERISTICS SVANOVIR® CSFV-Ab

In comprehensive studies including samples from domestic and wild boars, SVANOVIR® CSFV-Ab demonstrates a well-balanced specificity and sensitivity. Among other studies, the high performance was demonstrated in an OIE compliant serum panel from Community Reference Laboratory Hannover and a well-defined panel from National Reference Swine Laboratory in Perugia. SVANOVIR® CSFV-Ab detected antibodies to high, medium and low virulent strains, in sera of convalescent pigs (>21dpi) and during early phase of infection (< 21dpi). Cross-reactivity to non-CSF/ruminant *Pestivirus* was absent (BVDV) or low (BDV). The assay fulfills the requirements set by OIE.

Accurate results were also seen in domestic and wild boar populations with a history of freedom of disease, and in vaccinated herds. More information about the validation studies is provided in the "Performance Review" document.

Serum analysis of	Sensitivity	Specificity
Well-defined OIE panel from CRL Hannover	100%	95.6%
n=91 field samples <sup>1,2</sup> from domestic populations with history of freedom of infection	n.a.	100%
n=46 field samples <sup>1</sup> from wild boars with history of freedom of infection	n.a.	100%

Samples from <sup>1</sup>Sweden and <sup>2</sup>France

## Complementary products

<b>SVANOVIR® ASFV-Ab</b>	Highly specific assay for detecting exposure to African Swine Fever Virus
<b>SVANOVIR® PRV gB-Ab</b>	Surveillance of exposure to PRV in non-vaccinated swine populations
<b>SVANOVIR® PRV gE-Ab</b>	A parallel test for DIVA vaccines enabling the detection of Aujeszky's disease in vaccinated swine populations
<b>SVANOVIR® TGEV/PRCV-Ab</b>	The first antibody ELISA that accurately differentiates between Transmissible Gastroenteritis Virus and Porcine Respiratory Coronavirus

Boehringer Ingelheim Svanova  
Box 1545  
SE-751 45 Uppsala, Sweden

[www.svanova.com](http://www.svanova.com)

svanova 